Fax: (713) 794-1934
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor†
Article first published online: 8 APR 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 21, pages 4939–4947, 1 November 2011
How to Cite
Park, M. S., Patel, S. R., Ludwig, J. A., Trent, J. C., Conrad, C. A., Lazar, A. J., Wang, W.-L., Boonsirikamchai, P., Choi, H., Wang, X., Benjamin, R. S. and Araujo, D. M. (2011), Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer, 117: 4939–4947. doi: 10.1002/cncr.26098
Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL, and at the 14th Annual Meeting of the Connective Tissue Oncology Society, November 13-15, 2008, London, United Kingdom.
- Issue published online: 19 OCT 2011
- Article first published online: 8 APR 2011
- Manuscript Accepted: 26 JAN 2011
- Manuscript Revised: 20 JAN 2011
- Manuscript Received: 1 NOV 2010
- solitary fibrous tumors;
- soft tissue sarcoma;
- anti-angiogenesis inhibitors
Hemangiopericytomas and malignant solitary fibrous tumors (HPC/SFT) are rare, closely related sarcomas with unpredictable behavior that respond infrequently to chemotherapy. An optimal systemic treatment strategy for advanced HPC/SFT has not yet been identified.
We retrospectively analyzed the records of 14 patients with histopathologically confirmed HPC/SFT who were treated at The University of Texas MD Anderson Cancer Center between May 2005 and June 2007. All patients were treated with temozolomide 150 mg/m2 orally on days 1-7 and days 15-21 and bevacizumab 5 mg/kg intravenously on days 8 and 22, repeated at 28-day intervals. Computed tomography assessment of tumor size and density (Choi criteria) was used to determine the best response to therapy. The Kaplan–Meier method was used to estimate progression-free survival.
The median follow-up period was 34 months. Eleven patients (79%) achieved a Choi partial response, with a median time to response of 2.5 months. Two patients (14%) had stable disease as the best response, and 1 patient (7%) had Choi progressive disease as the best response. The estimated median progression-free survival was 9.7 months, with a 6-month progression-free rate of 78.6%. The most frequently observed toxic effect was myelosuppression.
Combination therapy with temozolomide and bevacizumab is a generally well-tolerated and clinically beneficial regimen for HPC/SFT patients. Additional investigation in a controlled, prospective trial is warranted. Cancer 2011;. © 2011 American Cancer Society.